You are currently logged into
POZ Directory - My Account or Log Out
POZ POZ
  • Home
  • Basics
    • Basics
    • Introduction
    • HIV Transmission and Risks
    • HIV Testing
    • HIV Prevention
    • Newly Diagnosed
    • Starting HIV Treatment
    • HIV Medications
    • HIV Drug Assistance Programs
    • HIV and Liver Disease
    • VIH/SIDA en Español
  • News
    • News
    • Newsfeed
    • Science News
    • Features
    • Opinions
    • Conferences
    • Slideshows
    • Videos
    • POZ at Home
    • POZ TV
    • POZ Stories
    • POZ 100
    • By Author
    • RSS Links
  • Hot Topics
    • Hot Topics
    • POZ Awards
    • POZ at 25
    • POZ 100
    • Advocacy
    • COVID-19
    • Criminalization
    • Cure
    • Long-Term Survivors
    • Newly Diagnosed
    • PrEP
    • Prevention
    • Undetectable (U=U)
    • Youth
  • Magazine
    • Magazine
    • Current Issue
    • Archives
    • Digital Editions
    • POZ Focus
    • POZ en Español
    • Subscriptions
    • Email Newsletters
  • Blogs
    • Blogs
    • Recent Posts
    • Browse Bloggers
    • RSS Links
  • Community
    • Community
    • POZ Personals
    • POZ Stories
    • POZ 100
    • Community
    • AIDS Is Everyday
    • Forums
    • Polls
    • Surveys
    • Quizzes
    • Ask POZ
    • Services Directory
    • Calendar
    • Jobs
    • Bookstore
  • About Us
    • About Us
    • About Us
    • Masthead
    • Awards
    • Press Releases
    • Advertise
    • Contact Us
  • Facebook
  • Twitter

© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

© 2021 Smart + Strong.
All Rights Reserved.
Terms of use and
Your privacy.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.

Advertisement

Share


Twitter
Facebook
Pinterest
Tumblr
Email

#paritaprevir

Tweet
  • Share

Major Liver Meeting Points to Continued Progress in Hep C Fight

Highlights from presentations at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.

FDA Green Lights AbbVie’s Technivie for Genotype 4 of Hepatitis C

The FDA has approved AbbVie’s single-tablet combination regimen Technivie plus ribavirin to treat genotype 4 of hepatitis C virus among...

How Sure Is a Hep C Cure?

Once you’ve officially rid yourself of hepatitis C, how certain can you be that the virus is gone for good?

Harvoni and Sovaldi/Daclatasvir Safer to Mix With HIV Meds

Harvoni and the combination of Sovaldi and daclatasvir were the least likely to cause a severe reaction with the HIV regimens of a cohort of H...

High Hep C Cure Rates for Viekira Pak Among Those Coinfected With HIV

Viekira Pak plus ribavirin boasts a hepatitis C cure rate in the low-90 percent range among those with genotype 1 of the virus who are coinfec...

AbbVie Viekira Pak

FDA Approves AbbVie’s Hepatitis C Regimen Viekira Pak

The U.S. Food and Drug Administration has approved AbbVie’s Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with...

Advertisement

Stay Logged In?

You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.

You Have Been Logged Out

Click here to log back in.